Guangzhou Innogen Pharmaceutical Group Co., a Chinese biotech firm looking to tap the vast domestic market for obesity drugs, surged as much as 296% in its trading debut in Hong Kong.
Shares of Innogen, which focuses on diabetes and metabolic diseases, climbed to HK$74 Friday, compared with its initial public offering price of HK$18.68. The company raised nearly HK$683 million ($87 million) in its IPO.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.